EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer

Ana Alfano, Eduardo G A Cafferata iD, Mariela Gangemi, Alejandro Nicola Candia iD, Cristian M Malnero, Ismael Bermudez, Mauricio Vargas Lopez iD, Gregorio David Ríos, Cecilia Rotondaro, Nicasio Cuneo, David T Curiel iD, Osvaldo L Podhajcer und 1 weitere

International Journal of Molecular Sciences · 10.06.2023 · 24 (12) · 9992

DOI: 10.3390/ijms24129992 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 10.06.2023. Verfasst von Ana Alfano und 12 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Cellular Therapy, Instituto Leloir, IIBBA-CONICET, Avenida Patricias Argentinas 435, Ciudad Autónoma de Buenos Aires C140…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Uterine Cervical Neoplasms, Ovarian Neoplasms, Adenoviridae Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, National Agency for Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

More than one million women are diagnosed annually worldwide with a gynecological cancer. Most gynecological cancers are diagnosed at a late stage, either because a lack of symptoms, such as in ovarian cancer or limited accessibility to primary prevention in low-resource countries, such as in cervical cancer. Here, we extend the studies of AR2011, a stroma-targeted and tumor microenvironment responsive oncolytic adenovirus (OAdV), whose replication is driven by a triple hybrid promoter. We show that AR2011 was able to replicate and lyse in vitro fresh explants obtained from human ovarian cancer, uterine cancer, and cervical cancer. AR2011 was also able to strongly inhibit the in vitro growth of ovarian malignant cells obtained from human ascites fluid. The virus could synergize in vitro with cisplatin even on ascites-derived cells obtained from patients heavily pretreated with neoadjuvant chemotherapy. AR2011(h404), a dual transcriptionally targeted derived virus armed with hCD40L and h41BBL under the regulation of the hTERT promoter, showed a strong efficacy in vivo both on subcutaneous and intraperitoneally established human ovarian cancer in nude mice. Preliminary studies in an immunocompetent murine tumor model showed that AR2011(m404) expressing the murine cytokines was able to induce an abscopal effect. The present studies suggest that AR2011(h404) is a likely candidate as a novel medicine for intraperitoneal disseminated ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oncolytic VirotherapyUterine Cervical NeoplasmsOvarian NeoplasmsAdenoviridae InfectionsOncolytic VirusesFemaleHumansMiceAnimalsAdenoviridaeAscitesMice, NudeTumor MicroenvironmentCell Line, TumorXenograft Model Antitumor Assays

Stichwörter der Autor:innen

adenoviruscytokinesgene therapygynecologic neoplasmsovarian cancer

Autor:innen und Institutionen

  • Laboratory of Molecular and Cellular Therapy, Instituto Leloir, IIBBA-CONICET, Avenida Patricias Argentinas 435, Ciudad Autónoma de Buenos Aires C1405BWE, Argentina.
  • Facultad de Ingeniería, Universidad Argentina de la Empresa, Lima 775, Ciudad Autónoma de Buenos Aires C1073AAO, Argentina.
  • Servicio de Ginecología, Departamento de Cirugía, Hospital Municipal de Oncología Maria Curie, Avenida Patricias Argentinas 750, Ciudad Autónoma de Buenos Aires C1405BWE, Argentina.
  • Division of Cancer Biology, Department of Radiation Oncology, School of Medicine, Washington University in St. Louis, St. Louis, MO 63110, USA.

ORCID-Profile: Eduardo G A Cafferata, Alejandro Nicola Candia, Mauricio Vargas Lopez, David T Curiel, Maria Veronica Lopez

Förderung

  • NCI NIH HHS
  • NIH HHS
  • National Agency for Promotion of Science
  • Technology and Innovation, The Instituto Nacional del Cáncer, the Consejo Nacional de Investigaciones Científicas y Técnicas
  • National Institutes of Health
  • Department of Defense Ovarian Cancer Research Program

Zitieren

APA

Alfano, A., Cafferata, E. G. A., Gangemi, M., Nicola Candia, A., Malnero, C. M., Bermudez, I., Lopez, M. V., Ríos, G. D., Rotondaro, C., Cuneo, N., Curiel, D. T., Podhajcer, O. L., & Lopez, M. V. (2023). In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer. International Journal of Molecular Sciences, 24(12), 9992. https://doi.org/10.3390/ijms24129992

Vancouver

Alfano A, Cafferata EGA, Gangemi M, Nicola Candia A, Malnero CM, Bermudez I, et al. In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer. International Journal of Molecular Sciences. 2023;24(12):9992. doi:10.3390/ijms24129992

BibTeX
@article{Alfano2023,
  author = {Alfano, Ana and Cafferata, Eduardo G A and Gangemi, Mariela and Nicola Candia, Alejandro and Malnero, Cristian M and Bermudez, Ismael and Lopez, Mauricio Vargas and Ríos, Gregorio David and Rotondaro, Cecilia and Cuneo, Nicasio and Curiel, David T and Podhajcer, Osvaldo L and Lopez, Maria Veronica},
  title = {In Vitro and In Vivo Efficacy of a Stroma-Targeted, Tumor Microenvironment Responsive Oncolytic Adenovirus in Different Preclinical Models of Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {12},
  pages = {9992},
  doi = {10.3390/ijms24129992}
}
Kostenlos starten →